MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

NCT04834024 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma and Marginal Zone Lymphoma

Interventions

DRUG: Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
DRUG: lenalinomide

Sponsor

Beijing Mabworks Biotech Co., Ltd.